PTC Therapeutics (PTCT) was upgraded by Raymond James Financial, Inc. to "moderate buy".
PTC Therapeutics (PTCT) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $108.00 price target on the stock.
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty [Yahoo! Finance]
PTC Therapeutics (PTCT) had its "hold" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $76.00 price target on the stock, down from $91.00.
PTC Therapeutics (PTCT) was upgraded by Truist Financial Corporation to "strong-buy".